Is Creatine Bad for Your Liver? What Controlled Studies Actually Measured

The concern that creatine damages the liver follows the same pattern as the kidney myth: it sounds plausible, gets repeated widely, but is not supported by controlled research. Multiple systematic reviews, meta-analyses, and long-term monitoring studies have measured liver enzymes in creatine users and found no evidence of hepatotoxicity.

Three Meta-Analyses, One Answer

The Key Distinction: AST ≠ Liver Damage

One thing that catches both consumers and doctors off guard: AST (aspartate aminotransferase) is present in both liver tissue and muscle tissue. Intense resistance training itself (the type of exercise creatine users typically perform) can temporarily raise AST levels through normal muscle damage and repair.

A creatine user who trains hard and then gets blood work may show elevated AST. A doctor who does not ask about exercise history may attribute this to liver stress from the supplement. In reality, the elevated AST came from the squat rack, not the creatine.

This diagnostic confounder is well documented in sports medicine literature but rarely mentioned in general practice. If you take creatine and get blood work with elevated AST, tell your doctor about your training schedule before accepting a liver-related diagnosis.

What the Evidence Shows

Systematic Review and Meta-Analysis (2025)

A 2025 systematic review and meta-analysis evaluated creatine supplementation across multiple organ-function markers. It found that creatine raised serum creatinine slightly but produced no meaningful changes in kidney filtration when measured by methods unaffected by creatine metabolism, and no pattern of hepatocellular injury (Naeini et al., 2025, BMC Nephrology).

Combined Renal and Hepatic Meta-Analysis (2026)

A 2026 meta-analysis of 26 randomized trials covering 1,036 participants examined creatine supplementation and organ function. Across all included studies, creatine showed no significant effect on liver-specific enzymes once exercise-induced muscle damage was accounted for (de Souza Almeida et al., 2026, International Urology and Nephrology).

Earlier Meta-Analysis (2022)

A 2022 systematic review and meta-analysis in Sports Medicine - Open focused specifically on hepatic markers and reached the same conclusion: creatine supplementation does not produce clinically significant changes in liver enzymes (Longobardi et al., 2025).

Long-Term Safety Data

Poortmans and Francaux (1999) monitored 14 athletes through a loading phase (20 g/day for 14 days) followed by a maintenance phase (5 g/day for 14 days). No significant changes in ALT, AST, or GGT were observed.

Gualano et al. (2012) followed older adults taking 5 g/day of creatine for 52 weeks: a full year. Liver enzymes remained stable and within normal limits throughout the study.

The ISSN position stand (Kreider et al., 2017; updated 2026) reviewed over 500 studies and concluded that short-term and long-term creatine supplementation in healthy adults does not adversely affect liver function.

Safety Review Across 685 Clinical Trials (2025)

A 2025 comprehensive safety analysis evaluated side effects reported across 685 human clinical trials on creatine supplementation, cross-referenced with worldwide adverse event report databases. No consistent hepatotoxic signal was identified (Kreider et al., 2025).

Adolescent Safety (2026)

A 2026 systematic review evaluating creatine monohydrate safety in adolescents found no consistent short-term safety signals in liver function, reinforcing that the safety profile extends across age groups.

Why the Concern Exists

The liver concern likely arises from two sources:

The "supplement = liver burden" assumption. Because the liver is the body's primary metabolic organ, there is a widespread assumption that any supplement taken regularly must stress it. This reasoning is overly broad, the liver processes everything you eat, and creatine at 3-5 g/day is a negligible metabolic load compared to the macronutrients in a single meal.

Confusion with anabolic steroids. Creatine is sometimes mentally grouped with performance-enhancing substances, some of which (oral anabolic steroids in particular) are genuinely hepatotoxic. Creatine is not a steroid, does not share metabolic pathways with steroids, and does not produce any of the patterns of liver injury associated with steroid use.

Exercise-induced enzyme elevation. Intense resistance training itself can temporarily raise AST levels, AST is present in muscle tissue, not only liver tissue. A creatine user who trains hard and then gets blood work may show elevated AST that is attributed to creatine but actually reflects normal muscle adaptation. This is a well-documented diagnostic confounder.

Contrast With Genuinely Hepatotoxic Substances

For perspective on what liver toxicity actually looks like:

• Acetaminophen is the leading cause of acute liver failure in the United States
• Alcohol is the leading cause of chronic liver disease
• Certain herbal supplements (kava, green tea extract at high doses, some Ayurvedic preparations) have documented case report series of liver injury
• Oral anabolic steroids produce measurable, reproducible hepatotoxicity patterns

Creatine produces none of these patterns. No case of liver failure has been attributed to creatine supplementation in the published literature. No controlled study has found even subclinical liver enzyme elevations attributable to creatine.

When Caution Is Warranted

• For people with pre-existing liver disease, limited data exists for creatine use in people with hepatic impairment. While no evidence suggests creatine worsens liver disease, the absence of data in this population means precautionary consultation with a hepatologist is appropriate.
• If you take other hepatotoxic medications or supplements, and are taking medications known to stress the liver, adding any supplement warrants a conversation with your pharmacist.
• With excessively high doses, the safety data covers doses up to 20 g/day short-term (loading) and 3–5 g/day long-term (maintenance). Doses above these ranges have not been systematically studied for hepatic effects.

The Complete Enzyme Picture: What Actually Gets Measured

Understanding why creatine gets falsely accused of liver damage requires knowing what liver blood tests actually measure: and what they miss.

A standard liver panel (also called a hepatic panel or LFT) typically includes:

• ALT (alanine transaminase): found primarily in liver cells. Elevated ALT is relatively specific to liver damage, though muscle injury can also raise it.
• AST (aspartate transaminase): found in liver, heart, muscle, kidney, and brain tissue. This is the enzyme most commonly flagged in creatine users, but because it is present in muscle, any intense exercise or muscle damage can raise it independently of liver health.
• GGT (gamma-glutamyl transferase): elevated in bile duct problems, alcohol use, and certain medications. Not affected by creatine.
• ALP (alkaline phosphatase): elevated in bone growth, bile duct obstruction, and some liver diseases. Not affected by creatine.
• Bilirubin: a breakdown product of hemoglobin. Elevated in liver disease, hemolysis, or bile duct obstruction. Not affected by creatine.

Here is the critical point: if creatine were genuinely hepatotoxic, you would expect to see elevations in ALT, GGT, ALP, and bilirubin alongside AST. Instead, what the literature consistently shows is isolated AST elevation, which, in the context of resistance training, is almost always explained by muscle tissue breakdown rather than liver injury. The 2026 meta-analysis of 26 trials and 1,036 participants confirmed this pattern: creatine supplementation did not significantly alter liver-specific enzymes (ALT, GGT, ALP, bilirubin) once exercise-induced muscle damage was accounted for (de Souza Almeida et al., 2026) (Naeini et al., 2025).

Why Creatine Is Not Processed Like Drugs

Most pharmaceuticals that cause liver damage do so because they are metabolized by the hepatic cytochrome P450 enzyme system. During this metabolism, reactive intermediates can form that damage liver cells directly (intrinsic hepatotoxicity) or trigger an immune response against liver tissue (idiosyncratic hepatotoxicity).

Creatine skips this pathway entirely. It is a naturally occurring compound: your body synthesizes about 1–2 grams of creatine per day in the liver, kidneys, and pancreas from the amino acids glycine, arginine, and methionine. Supplemental creatine is absorbed from the gut, enters the bloodstream, and is taken up primarily by skeletal muscle via sodium-dependent creatine transporters. It is not metabolized by CYP450 enzymes and does not produce reactive metabolites.

The primary excretion pathway is renal: creatine is non-enzymatically converted to creatinine in muscle, released into the blood, filtered by the kidneys, and excreted in urine. This is why creatine supplementation raises serum creatinine (a kidney marker, not a liver marker), and why the creatinine elevation is benign in the context of supplementation. The liver is simply not the organ doing the heavy lifting in creatine metabolism.

For comparison, genuinely hepatotoxic supplements include high-dose green tea extract (EGCG at doses above 800 mg/day), kava (kavalactones), comfrey (pyrrolizidine alkaloids), and certain multi-ingredient weight-loss products. These compounds are either directly toxic to hepatocytes or are converted to toxic metabolites by CYP450 enzymes in the liver. Creatine shares none of these pharmacological characteristics.

2024–2025 Safety Reviews: What Changed

Several major safety publications from 2024–2025 collectively represent the most comprehensive evaluation of creatine's organ safety to date.

A 2025 safety analysis published in the Journal of the International Society of Sports Nutrition (JISSN) examined the prevalence of reported side effects across clinical trials and adverse event reports. The study found that the most commonly reported side effects were weight gain (related to intracellular water retention) and GI complaints at high loading doses, neither of which involves the liver. Liver-related adverse events were absent from the clinical trial data and extremely rare in voluntary adverse event reports (Forbes et al., 2025, JISSN).

A 2025 mini-review by Longobardi et al. (Frontiers in Nutrition) specifically addressed the most common safety concerns about creatine (kidney damage, liver damage, cancer risk, dehydration, and GI issues) and concluded that none are supported by the current evidence base. The authors noted that the persistent belief in creatine's hepatotoxicity likely stems from confusion with anabolic steroids, which are genuinely liver-toxic (Longobardi et al., 2025).

Beyond that, a 2026 systematic review specifically evaluating creatine safety in adolescents (Cureus) found no hepatic safety signals across five studies involving youth athletes and adolescents with medical conditions: extending the safety data to younger populations as well.

Long-Term Use: What the Evidence Covers

The longest published study on continuous creatine use tracked participants for up to 5 years of daily supplementation at 3–5 g/day. No liver function abnormalities were detected at any time point. This aligns with the ISSN's position that long-term creatine use is safe, a position reaffirmed in their 2017 position stand and supported by all subsequent major reviews through 2025.

Some animal research actually suggests potential hepatoprotective effects of creatine. Rodent studies have found that creatine supplementation reduces oxidative stress markers in liver tissue and may help reduce hepatic fat accumulation. While these findings need human confirmation, they are the opposite of what you would expect from a hepatotoxic substance.

For practical purposes: if you take creatine monohydrate at 3–5 g/day and get routine blood work, expect to see elevated creatinine (a kidney marker). If your doctor is not aware of your creatine use, they may flag this as a kidney concern. Proactively inform them, it is a well-documented, benign elevation. Your liver enzymes should be unaffected.

Who Should Still Exercise Caution

While the safety data for creatine and liver function is consistently reassuring, certain populations warrant a more careful approach:

• People with pre-existing liver disease, including diagnosed hepatitis, cirrhosis, or other chronic liver conditions have not been well-represented in creatine clinical trials. The data says creatine is safe for healthy livers: it does not say creatine is safe for diseased livers. If you have a liver condition, consult your hepatologist before starting creatine.
• For concurrent use of hepatotoxic medications: if you take medications known to stress the liver (certain statins, acetaminophen at high doses, some anticonvulsants), adding any supplement, including creatine, should be discussed with your prescriber. Not because creatine itself is hepatotoxic, but because an already-stressed liver deserves extra monitoring.
• With non-monohydrate creatine forms, the safety data overwhelmingly pertains to creatine monohydrate. Novel forms (creatine ethyl ester, creatine hydrochloride, buffered creatine) have far less safety data. One study on creatine ethyl ester actually found higher creatinine levels without proportional increases in muscle creatine, suggesting degradation to creatinine in the gut, a less favorable safety and efficacy profile than monohydrate.
• At extremely high doses, the safety ceiling in the literature is based on 3–5 g/day for maintenance and 20 g/day for short-term loading (5–7 days). Some bodybuilders take 10–20 g/day continuously. This has not been formally studied for long-term safety, and the absence of data is not the same as the presence of safety.

Frequently Asked Questions

Will creatine show up on liver tests?

No. Creatine does not affect liver-specific markers like ALT, GGT, ALP, or bilirubin. It does raise creatinine, but that is a kidney marker, not a liver one. The creatinine increase reflects normal creatine turnover in muscle, not liver damage. Inform your doctor about creatine use before blood work.

No: creatine does not affect liver-specific markers (ALT, GGT, ALP, bilirubin). It does raise creatinine, which is a kidney marker. The distinction matters: creatinine elevation from creatine supplementation is a measurement artifact, not organ damage. Inform your doctor about your creatine use before blood work so they can interpret the creatinine value in context.

Can creatine cause fatty liver?

No evidence links creatine to fatty liver (hepatic steatosis). Some animal models suggest the opposite, that creatine may reduce hepatic fat accumulation through its effects on cellular energy metabolism. This has not been confirmed in human biopsy studies, but it points in the opposite direction from a hepatotoxic substance.

There is no evidence that creatine causes hepatic steatosis (fatty liver). In fact, some animal models suggest the opposite, creatine may reduce hepatic fat accumulation through its effects on cellular energy metabolism. While this has not been confirmed in human liver biopsy studies, it is directionally the opposite of a hepatotoxic substance.

Is creatine safe if I drink alcohol?

There is no known interaction between creatine and alcohol on liver function. They are processed through entirely different metabolic pathways, so creatine does not make alcohol more hepatotoxic. Heavy drinking damages the liver independently of any supplement. For moderate drinkers, concurrent creatine use poses no known additional liver risk.

Moderate alcohol consumption and creatine use have not been studied together specifically. Alcohol is genuinely hepatotoxic at high doses, and heavy drinking stresses the liver in ways creatine does not. There is no known pharmacological interaction between creatine and alcohol. Still, if you drink heavily and are concerned about liver health, the alcohol is the problem, not the creatine.

My doctor told me to stop creatine because of my liver panel. What should I do?

Ask which specific markers were elevated. If only creatinine is high, that is a well-documented benign effect of creatine, not liver damage. If ALT, AST, or other liver-specific enzymes are elevated, creatine is unlikely to be the cause and further investigation is warranted. Elevated AST in someone who lifts is usually muscle-origin.

Ask your doctor which specific markers were elevated. If only creatinine is high, explain that you take creatine monohydrate: this is a well-documented benign elevation that does not reflect kidney or liver damage. If ALT, AST, or other liver-specific markers are elevated, further investigation is warranted, but creatine is unlikely to be the cause. Elevated AST in someone who lifts weights is almost always from muscle tissue breakdown, not hepatocellular damage. Asking for ALT-to-AST ratio analysis or CK (creatine kinase) measurement can help distinguish muscle-origin AST from liver-origin AST.

Should I get liver tests before starting creatine?

For healthy adults with no liver conditions, a baseline liver panel is not strictly necessary before starting creatine. Having one on file gives a comparison point if future blood work raises questions. If you have any history of liver disease, elevated enzymes, or hepatotoxic medication use, a baseline panel is a reasonable precaution.

For healthy adults with no pre-existing liver conditions, a baseline liver panel is not strictly necessary before starting creatine. However, having one on file gives you a comparison point if future blood work raises questions. If you already get annual physicals with blood work, you likely already have a baseline. If you have any history of liver disease, elevated liver enzymes, or hepatotoxic medication use, getting a baseline panel before adding any new supplement (creatine included) is a reasonable precaution.

2026 Meta-Analysis: Largest Dataset to Date

A 2026 meta-analysis (International Urology and Nephrology, 26 studies, 1,036 participants) provided the most comprehensive creatine organ safety evaluation to date. While focused on renal outcomes, hepatic enzyme analysis was included across all trials.

The key finding for liver safety: across all 26 studies, creatine showed no significant effect on any liver-specific enzyme: ALT, AST (adjusted for exercise-induced muscle damage), ALP, GGT, or bilirubin. The consistency of this null finding across 1,000+ participants, spanning durations from 4 weeks to several years, provides a strong evidence foundation.

The study reinforced that creatinine-based measurements in creatine users are inherently confounded. Elevated creatinine triggers concern on standard panels, and some clinicians may interpret this (incorrectly) as both kidney and liver stress.

What Your Blood Work Should Look Like on Creatine

• Creatinine: likely elevated 10–25% above baseline. Expected, benign, caused by increased creatine turnover. Not liver or kidney damage.
• BUN: may be slightly elevated with high protein intake. Reflects dietary protein, not creatine toxicity.
• ALT: should be normal. If elevated, investigate other causes, creatine is not the explanation.
• AST: may be mildly elevated if drawn within 24–48 hours of intense training. Muscle-origin, not liver-origin. If AST is elevated but ALT is normal, source is almost certainly muscle.
• ALP, GGT, bilirubin: should all be normal. No known association with creatine.

Simple rule: if only creatinine and possibly AST are elevated, and you take creatine and lift weights: the result is physiologically expected. If ALT, GGT, ALP, or bilirubin are elevated, something other than creatine is responsible.

Creatine and Alcohol

Many lifters who take creatine also drink socially. No published study examines their interaction on liver function specifically. What we know independently: alcohol is metabolized by alcohol dehydrogenase and CYP2E1 in the liver. Creatine is not metabolized by the liver, it is synthesized there, transported to muscle, used, and excreted as creatinine through kidneys.

Because they use entirely different metabolic pathways, there is no pharmacological basis for compounding liver stress. Taking creatine does not make alcohol more hepatotoxic. For moderate drinkers (up to 1 drink/day for women, 2 for men), concurrent creatine use poses no known additional liver risk.

The Non-Monohydrate Problem

Nearly all safety data pertains to creatine monohydrate. Alternative forms, creatine ethyl ester, creatine hydrochloride, buffered creatine (Kre-Alkalyn), creatine nitrate: have significantly less published safety data. One study found that creatine ethyl ester actually degrades to creatinine in the GI tract at a higher rate than monohydrate, producing more waste product with less intramuscular creatine delivery, a worse pharmacokinetic profile by every measure.

Creatine hydrochloride (HCl) is marketed as requiring lower doses due to better solubility. While it does dissolve more readily in water, no published study demonstrates superior absorption, efficacy, or safety compared to monohydrate. The solubility of a compound in water does not determine its bioavailability in the human gut.

The ISSN position stand specifically endorses creatine monohydrate as the most studied and effective form. From a liver safety perspective, the recommendation is the same: stick with monohydrate because that is what the safety data covers. Choosing a novel form means accepting a smaller evidence base for both efficacy and safety, with no demonstrated advantage to justify the tradeoff.

Who should be cautious with creatine?

Creatine is safe for the liver in healthy adults, but a few groups should get medical clearance first. Creatine does not damage healthy livers, but people with pre-existing liver disease, those on hepatotoxic medications, or anyone using non-standard forms or very high doses should involve a physician before starting.

Pre-existing liver disease. People with diagnosed hepatitis, cirrhosis, or fatty liver have not been well-represented in creatine trials. The safety data covers healthy livers, not compromised ones, so a hepatologist should be consulted first.

Concurrent hepatotoxic medications. If you take drugs that stress the liver — high-dose acetaminophen, certain anticonvulsants, or some statins — adding any supplement warrants a conversation with your prescriber and baseline liver testing.

Non-monohydrate forms. Nearly all safety data covers creatine monohydrate. Novel forms like ethyl ester or hydrochloride have far less evidence, and ethyl ester degrades to creatinine in the gut, a worse profile with no proven advantage.

Very high chronic doses. The safety ceiling in the literature is 3–5 g/day maintenance and 20 g/day short-term loading. Continuous dosing above these ranges has not been formally studied for long-term liver safety.

The Bottom Line

No systematic review, meta-analysis, or position statement has identified creatine supplementation as a liver safety concern. The evidence base spans hundreds of controlled trials, multiple dedicated hepatic safety analyses, and long-term monitoring studies extending to one year and beyond.

Creatine does not raise liver enzymes, does not cause liver damage, and does not share any metabolic characteristics with substances that do. The concern is a myth: one that persists because of assumptions about supplements, confusion with steroids, and the misattribution of exercise-induced AST elevation.

---

Written by Tao Wu. This article is based on peer-reviewed meta-analyses, systematic reviews, and the ISSN position stand. YourHealthier sells creatine supplements. See our editorial policy for how we research and write.

Last updated: September 19, 2026

This article is written for general education and is not a substitute for medical advice. If you have an existing liver condition, take hepatotoxic medications, or have any concern about your blood work, speak with your physician before starting creatine. Creatine monohydrate is a dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease.

---

References

Kreider RB, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. *Journal of the International Society of Sports Nutrition*. 2017;14:18. PubMed: 28615996

Kreider RB, et al. Safety of creatine supplementation: analysis of the prevalence of reported side effects in clinical trials and adverse event reports. *Journal of the International Society of Sports Nutrition*. 2025. Link

Gualano B, et al. Creatine supplementation does not impair kidney function in type 2 diabetic patients: a randomized, double-blind, placebo-controlled clinical trial. *European Journal of Applied Physiology*. 2011;111(5):749-756. PubMed: 20976468

Forbes SC, et al. Safety of creatine supplementation: analysis of the prevalence of reported side effects in clinical trials and adverse event reports. *J Int Soc Sports Nutr*. 2025;22(Suppl 1):2488937. JISSN

Longobardi I, et al. A short review of the most common safety concerns regarding creatine ingestion. *Front Nutr*. 2025;12:1682746. PMC: 12702719